Despite the predictive effect of the PD-L1 biomarker, there are still several limitations to its practical use, including variation over time and tumor locations [35], inconsistent prediction efficacy [36, 37], and unclear interactions with EGFR and ALK mutations [38]. This evidence concerns the gene EGFR and neoplasm.